title: Etanercept-induced leukemia: could increased mean corpuscular volume be a predictor of hematologic malignancy?
abstract: In rheumatology practice, anti-tumor necrosis factor (TNF) alpha agents are frequently used medications, more so in ankylosing spondylitis (AS). There are case reports, besides their adverse effects, such as infection and injection site reaction, suggesting these agents may cause solid or hematologic malignancies. Acute leukemia secondary to anti-TNF alpha agents has been rarely reported in patients with AS. In this case report, based on a patient who developed acute leukemia while on the treatment with etanercept, we will discuss whether it is possible to predict acute leukemia by monitoring the mean corpuscular volume in light of the literature.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey. ducansu@hotmail.com.
authors.forename: Döndü Üsküdar
authors.initials: DÜ
authors.lastname: Cansu
authors.affiliation: Division of Hematology, Eskişehir Osmangazi University, Eskisehir, Turkey.
authors.forename: Hava Üsküdar
authors.initials: HÜ
authors.lastname: Teke
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey.
authors.forename: Cengiz
authors.initials: C
authors.lastname: Korkmaz
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects; D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D004909:Erythrocyte Indices / Q000187:drug effects*; D000068800:Etanercept / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Acute myeloid leukemia; Ankylosing spondylitis; Etanercept; Mean corpuscular volume